GLP 1 medications have changed the way we treat obesity and metabolic disease. Semaglutide and tirzepatide are best known for weight loss, but their effects reach well beyond the number on a scale.
These drugs act on systems that regulate appetite, blood glucose, insulin, glucagon and the movement of food through the stomach. They also influence communication between the gut and brain. Large randomized trials have demonstrated benefits in cardiovascular disease, chronic kidney disease, obstructive sleep apnea and metabolic liver disease. Researchers are exploring other uses, including addiction and neurodegenerative disease, although the evidence there is much less settled.
For people over 50, the discussion needs to include what happens to muscle during substantial weight loss. Losing fat can improve health, but losing valuable lean tissue can work against strength and independence. Nutrition, resistance training and medical supervision deserve a place in the conversation from the start.
What Is GLP 1, and How Do These Drugs Work?
GLP 1 stands for glucagon like peptide 1. It’s an incretin hormone released mainly by intestinal cells after you eat.
The hormone helps coordinate several responses to a meal. It stimulates insulin secretion when blood glucose is elevated, suppresses glucagon, slows gastric emptying and sends signals to regions of the brain involved in appetite. Together, these effects increase satiety and reduce food intake.
Modern medications mimic or amplify those signals. Semaglutide, sold under names including Ozempic and Wegovy, is a GLP 1 receptor agonist.
Tirzepatide, sold as Mounjaro and Zepbound, works somewhat differently. It activates both GLP 1 receptors and receptors for glucose dependent insulinotropic polypeptide, or GIP. That makes it a dual GIP/GLP 1 agonist.
The two medications are related, but they aren’t identical. Their effects also appear to involve several interacting mechanisms. Hunger and fullness are biological processes, and these drugs change the signals involved in those processes. That helps explain why they can produce results that simply asking someone to exercise more willpower often cannot.
1. Weight Loss
Weight reduction is the most visible effect of this drug class. Depending on the medication, dose and population studied, trials have reported average losses ranging from roughly 10% to about 20% or more of starting body weight.
Tirzepatide has produced particularly substantial results. In the three year SURMOUNT 1 analysis of participants with obesity and prediabetes, average weight loss after 176 weeks was:
- 12.3% with 5 mg of tirzepatide
- 18.7% with 10 mg
- 19.7% with 15 mg
- 1.3% with placebo
Those reductions approach levels historically associated more closely with bariatric interventions than with conventional obesity medications. They also provide a starting point for understanding some of the broader metabolic benefits researchers are finding.
2. Type 2 Diabetes and Blood Glucose
GLP 1 medications were originally developed primarily to treat diabetes. They improve glucose regulation partly by increasing insulin secretion in response to elevated glucose and reducing glucagon.
Because the insulin response is largely dependent on glucose levels, these medications generally have a relatively low risk of severe hypoglycemia when used on their own. Combining them with insulin or sulfonylureas changes that risk and requires closer attention.
There’s also evidence that treatment can reduce progression from prediabetes to type 2 diabetes in certain patients. In the three year SURMOUNT 1 study, all participants in this analysis had obesity and prediabetes at baseline. During 176 weeks, type 2 diabetes developed in 1.3% of those receiving tirzepatide, compared with 13.3% receiving placebo.
That’s a substantial difference during treatment. It doesn’t mean everyone with prediabetes should automatically receive one of these drugs, but it shows how much their effects can extend beyond appearance or weight alone.
3. Cardiovascular Protection
The SELECT trial was a turning point in how these medications are understood. It enrolled 17,604 adults with overweight or obesity and established cardiovascular disease who did not have diabetes.
Semaglutide produced a 20% relative reduction in the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo.
The trial measured actual cardiovascular events. That matters because improving weight or a laboratory marker doesn’t always translate into fewer heart attacks and strokes.
Wegovy’s FDA labeling now includes reducing the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
Researchers are still investigating how much of the benefit comes from weight loss and how much may involve changes in blood pressure, glucose regulation, inflammation, vascular biology and other pathways. The outcome is established in the population studied, even as the mechanisms continue to be examined.
4. Kidney Protection
The FLOW trial studied semaglutide in people with type 2 diabetes and chronic kidney disease. Compared with placebo, semaglutide reduced the risk of the trial’s primary combined kidney and cardiovascular outcome by 24%.
The decline in estimated glomerular filtration rate was slower. Major cardiovascular events were reduced by 18%, and mortality from all causes was 20% lower.
Ozempic’s FDA indication now includes reducing the risk of sustained kidney function decline, end stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
For that patient population, kidney protection has moved beyond a proposed secondary benefit. It is supported by clinical trial outcomes and reflected in the medication’s indication.
5. Fatty Liver Disease and MASH
Metabolic dysfunction associated steatotic liver disease is increasingly common, especially among people with obesity, insulin resistance or type 2 diabetes. Its inflammatory form, metabolic dysfunction associated steatohepatitis, is usually shortened to MASH. It can progress to fibrosis, cirrhosis and liver failure.
In the phase 3 ESSENCE trial, semaglutide significantly improved liver histology in people with MASH and moderate to advanced fibrosis.
Wegovy now has an FDA indication, under accelerated approval, for adults with noncirrhotic MASH and moderate to advanced fibrosis consistent with stages F2 to F3. This is another example of the role of these medications expanding into conditions that often accompany metabolic disease.
6. Obstructive Sleep Apnea
Obesity is one of the strongest modifiable contributors to obstructive sleep apnea. The SURMOUNT OSA trials evaluated tirzepatide in adults with obesity and moderate to severe obstructive sleep apnea.
Treatment reduced the apnea hypopnea index, body weight, hypoxic burden, systemic inflammation and systolic blood pressure. Participants also reported improvements in sleep outcomes.
Zepbound is now FDA indicated for moderate to severe obstructive sleep apnea in adults with obesity. Its use in that setting is an established indication, rather than simply a possible application outside the approved labeling.
7. Heart Failure With Preserved Ejection Fraction
Obesity related heart failure with preserved ejection fraction, or HFpEF, is another area where trial results have been encouraging.
The STEP HFpEF trial enrolled 529 patients with obesity and HFpEF. Participants received semaglutide or placebo for 52 weeks.
Semaglutide led to substantially greater improvements in heart failure symptoms and physical limitations. It also increased the distance participants could walk in six minutes and reduced CRP, a marker of systemic inflammation.
Weight reduction probably accounts for some of these improvements. Investigators are continuing to study whether additional mechanisms contribute.
8. Alzheimer’s and Parkinson’s Disease
The neurological research deserves attention, but it also calls for restraint. Scientists are interested in whether GLP 1 signaling can influence neuroinflammation, insulin signaling in the brain and pathways involved in neurodegeneration.
Early laboratory work and observational findings generated enthusiasm about Alzheimer’s and Parkinson’s disease. The clinical evidence has been less convincing.
A 2026 systematic review and meta analysis of 14 randomized trials involving 1,260 participants found only a very small statistical improvement in global cognition. The authors concluded that the available evidence did not convincingly demonstrate a clinically meaningful neurological benefit or an effect that modifies the course of disease.
These medications therefore should not currently be presented as treatments for Alzheimer’s or Parkinson’s. The research is worth following, but the possible applications remain ahead of what the clinical findings can establish.
9. Alcohol, Addiction and Compulsive Behavior
Some patients taking GLP 1 medications report less interest in alcohol and other rewarding behaviors, as well as less interest in food. That has prompted research into the brain’s reward pathways and possible applications in alcohol use disorder, other substance use disorders, binge eating and compulsive behaviors.
There are plausible neurological mechanisms and preliminary findings that justify further study. The clinical evidence, however, is considerably weaker than the evidence for obesity, diabetes and cardiovascular indications.
A recent systematic review described many of the neuropsychiatric findings as hypothesis generating, with certainty ranging from moderate to very low.
For now, addiction treatment belongs in the category of emerging research. It is not an established GLP 1 indication.
What Side Effects Should People Know About?
The most common side effects involve the gastrointestinal tract: nausea, vomiting, diarrhea, constipation, abdominal discomfort and indigestion or reflux.
Symptoms often appear as the dose increases and may ease as the body adapts. Slower titration can sometimes improve tolerability, although changes to the dosing schedule should be made with the prescribing clinician.
Less common complications can be more serious.
Gallbladder Disease
Rapid weight loss itself raises the risk of gallstones, and GLP 1 medications have also been associated with acute gallbladder disease.
Pancreatitis
Acute pancreatitis has been reported. Persistent, severe abdominal pain, especially pain that radiates toward the back, requires prompt medical evaluation.
Dehydration and Kidney Injury
Substantial vomiting or diarrhea can cause dehydration and potentially acute kidney injury. People who are already vulnerable to kidney problems need particular attention.
Gastroparesis and Severe Gastrointestinal Disease
These medications slow gastric emptying and may aggravate severe gastrointestinal motility disorders. Ozempic, for example, is not recommended for patients with severe gastroparesis.
Diabetic Retinopathy
A rapid improvement in blood glucose may temporarily worsen diabetic retinopathy in some people. Anyone with established retinopathy warrants appropriate monitoring.
Anesthesia and Aspiration
Delayed gastric emptying can leave residual stomach contents that pose an aspiration risk during general anesthesia or deep sedation. Patients should tell their surgical, anesthesia and procedural teams that they take a GLP 1 medication.
Who Should Avoid These Medications?
The prescribing information for the individual medication is the place to start, because contraindications differ somewhat between drugs.
Semaglutide and tirzepatide carry boxed warnings concerning thyroid C cell tumors observed in rodents. Whether these medications cause medullary thyroid cancer in humans has not been established.
They are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or MTC, and in people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Serious hypersensitivity to the medication is another contraindication.
Other situations need individualized consideration. These include pregnancy, significant gastrointestinal disease, a history of pancreatitis or gallbladder disease, diabetic retinopathy, vulnerability to kidney injury and interactions with other diabetes medications. They shouldn’t all be treated as a single blanket rule.
One safety concern has also been reassessed. In January 2026, the FDA announced that its comprehensive evaluation did not identify an increased risk of suicidal ideation or suicidal behavior from GLP 1 medications. The agency requested removal of those warnings from the relevant labeling.
After 50, Muscle Preservation Deserves More Attention
Substantial weight loss usually includes both fat and lean mass. GLP 1 medications don’t make every pound lost come from body fat.
A 2026 meta analysis of 20 randomized trials involving 15,782 participants found that lean mass accounted for approximately 25% to 39% of total weight lost with incretin based therapies, depending on the drug. The proportion was broadly comparable with weight loss from lifestyle intervention alone. Resistance training substantially improved lean mass preservation.
That comparison helps put the concern in perspective. The issue isn’t necessarily that these drugs uniquely destroy muscle. They can produce large weight losses quickly, and older adults may have less muscle to spare.
After 50, preserving skeletal muscle becomes increasingly important for strength, glucose disposal, mobility, fall prevention, bone health and independence. A treatment plan that pays attention only to the scale can miss those priorities.
For older adults using these medications, the accompanying plan should generally emphasize progressive resistance training, adequate dietary protein, sufficient calories and micronutrients, and monitoring of strength and body composition when appropriate.
The aim is to lose excess fat while preserving muscle and function. The largest possible drop in body weight isn’t necessarily the best result.
Are GLP 1 Medications Longevity Drugs?
In the strict scientific sense, that description is premature. There is no randomized human trial showing that semaglutide or tirzepatide extends life in otherwise healthy people. Calling them proven antiaging drugs goes beyond the evidence.
Their relevance to healthspan is easier to support. Obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea and metabolic liver disease all contribute substantially to illness and death. In appropriately selected patients, these therapies can meaningfully improve several of those conditions.
SELECT provides a particularly useful example. Semaglutide reduced actual cardiovascular events in people with established cardiovascular disease and overweight or obesity. That is an outcome with clear relevance to healthspan, even though it does not establish a general longevity benefit for healthy people.
What This Means for Patients
GLP 1 therapies have become much more than weight loss medications. They can influence several interconnected disease pathways, and the strongest evidence supports benefits in obesity, type 2 diabetes, cardiovascular risk, chronic kidney disease, obstructive sleep apnea and metabolic liver disease. Evidence is also emerging in obesity related heart failure.
The neurological possibilities are at a different stage. Alzheimer’s disease, Parkinson’s disease, addiction and other applications remain areas of investigation, with preliminary findings that need stronger clinical support.
The benefits also have to be weighed against the risks. Gastrointestinal symptoms are common. Gallbladder disease, pancreatitis, dehydration related kidney injury, delayed gastric emptying and other complications require attention. Some patients should not receive these medications at all.
For people over 50, preserving lean tissue belongs alongside managing those risks. A useful treatment goal includes reducing excess visceral and body fat while maintaining, or ideally improving, muscle strength, physical capacity, metabolic health and cardiovascular fitness.
Used appropriately, these drugs may prove to be among the most consequential advances in metabolic medicine in decades. Their value lies in improving metabolic health and reducing disease risk. They should be understood as part of that work, with medical supervision and a plan to protect function as weight changes.
Key Scientific References
SELECT Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine.
FLOW Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine.
SURMOUNT OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine.
SURMOUNT 1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine.
STEP HFpEF Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine.
ESSENCE Investigators. Phase 3 Trial of Semaglutide in Metabolic Dysfunction Associated Steatohepatitis. New England Journal of Medicine.
U.S. Food and Drug Administration. Wegovy, Ozempic and Zepbound prescribing information and safety communications.
This article is for educational purposes and is not individualized medical advice. Medication selection, dosing and discontinuation should be discussed with a qualified healthcare professional.
About the GLP 1 Academy
GLP 1 Academy provides independent, science based education for every stage of the GLP 1 journey. Whether you’re considering a GLP 1 medication, taking one now or working to maintain your results, it helps you understand the science, ask better questions and make informed decisions with your healthcare professional.